Sophie He/LinkedIn
Aug 12, 2026, 06:01
Sophie He: Exploring Manufacturing Scalability and Cell Separation
Sophie He, Vice President Cell Therapy, Head of M&A and Partnering at Bracco shared a post on LinkedIn:
“In my latest interview with Technology Networks, I explored a critical but often overlooked bottleneck: manufacturing scalability and cell separation.
Cell and gene therapies have opened the potential to curing once – incurable conditions like sickle cell disease.
But approval is only half the story – the real question is, how many patients actually get treated?
Thank you to Izzy Hirst and Anna-Marie MacDonald at Technology Networks for the great conversation.
Full interview here.”
Stay updated with Hemostasis Today.
-
Aug 12, 2026, 08:16Chengyong Yang: Can Plasma Reveal Cell Specific Signals
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar